EGFR and breast cancer: In breast carcinoma cells, but not in CRC cells, YBX1 was found to bind to the promoter and act as a transcriptional activator of the EGFR gene.31 YBX1 mediated resistance to anti-ERBB2 therapy via a complex, RSK-dependent mechanism32 and prevents apoptosis in ERBB2-overexpressing breast cancer cells.33 In contrast to the well-known link between YBX1 and EGFR in breast or lung cancer, there is little knowledge about the interaction of YBX1 and the EGFR family in CRC.